1 week Ago By ABMN Staff
Farmers & Merchants Investments Inc. lessened its stake in GSK plc ( NYSE:GSK – Free Report ) by 8.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 4,062 shares of the pharmaceutical company’s stock after selling 393 shares during the period. Farmers & Merchants Investments Inc.’s holdings in GSK were worth $156,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Foundations Investment Advisors LLC increased its holdings in GSK by 13.3% in the 2nd quarter.
Foundations Investment Advisors LLC now owns 9,656 shares of the pharmaceutical company’s stock valued at $372,000 after buying an additional 1,132 shares during the period. Founders Financial Securities LLC boosted its position in shares of GSK by 3.1% during the 2nd quarter.
Founders Financial Securities LLC now owns 17,760 shares of the pharmaceutical company’s stock valued at $684,000 after acquiring an additional 542 shares in the last quarter. Naviter Wealth LLC increased its stake in GSK by 8.5% in the second quarter.
Naviter Wealth LLC now owns 47,661 shares of the pharmaceutical company’s stock valued at $1,852,000 after acquiring an additional 3,742 shares during the period. Legacy Capital Wealth Partners LLC acquired a new position in GSK in the second quarter worth about $753,000. Finally, TIAA Trust National Association lifted its stake in GSK by 11.
2% during the second quarter. TIAA Trust National Association now owns 7,824 shares of the pharmaceutical company’s stock worth $301,000 after purchasing an additional 788 shares during the period. 15.
74% of the stock is owned by institutional investors and hedge funds. GSK Stock Up 1.3 % Shares of NYSE GSK opened at $43.
67 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.
82 and a debt-to-equity ratio of 0.99. The company has a market cap of $90.
51 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 1.42 and a beta of 0.
64. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.
92. The firm’s 50-day simple moving average is $40.54 and its 200 day simple moving average is $41.
64. GSK Increases Dividend Analyst Ratings Changes Several equities research analysts have recently weighed in on the company. Citigroup upgraded GSK to a “strong-buy” rating in a research note on Monday, June 24th.
Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th.
Finally, The Goldman Sachs Group initiated coverage on shares of GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective on the stock.
Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $50.
00. Get Our Latest Report on GSK GSK Company Profile ( Free Report ) GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc ( NYSE:GSK – Free Report ). Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.
com's FREE daily email newsletter ..
